BCG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a novel class of oncolytic immunotherapies for patients with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic virus designed to selectively replicate in retinoblastoma (Rb) pathway-deficient tumor cells and trigger a systemic anti-tumor immune response through the expression of GM-CSF. CG Oncology is currently evaluating cretostimogene in the pivotal Phase 3 BOND-003 trial for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company successfully completed its initial public offering in early 2024 and is positioned as a leader in the bladder-sparing treatment landscape.